Table 3 Multivariate L1-Penalized Cox Regression Analysis
All Cause Death | HR [95% CI] |
|---|---|
Demographics: Age | 1.24 [1.02–1.52] |
Demographics: Driving Distance (km) | 0.94 [0.79–1.12] |
Lab: MELD Score | 1.35 [1.15–1.58] |
Lab: FIB–4 Score | 1.21 [1.03–1.41] |
Medication: Calcium Channel Blocker | 1.47 [0.88–2.45] |
Medication: Insulin | 1.15 [0.60–2.20] |
Medication: Sulfonylurea | 1.51 [0.87–2.62] |
Medication: Statin | 1.22 [0.81–1.82] |
Demographics: Native American/Alaskan/Hawaiian | 1.29 [0.89–1.87] |
Demographics: Baseline Year >= 2020 | 0.73 [0.48–1.12] |
Lab: Abnormal Alkaline Phosphatase | 2.19 [1.25–3.84] |
Composite outcome | HR [95% CI] |
Demographics: Age | 1.12 [0.96–1.29] |
Lab: MELD Score | 1.42 [1.27–1.58] |
Lab: FIB-4 Score | 1.43 [1.26–1.61] |
Comorbidity: Hyperlipidemia | 0.78 [0.59–1.04] |
Medication: ARB Inhibitor | 0.70 [0.46–1.06] |
Medication: Oral Diabetes Med | 1.35 [1.00–1.83] |
Medication: Aspirin/Clopidogrel | 0.77 [0.51–1.15] |
Demographics: Baseline Year >= 2020 | 0.74 [0.54–1.02] |
Decompensation Symptoms | HR [95% CI] |
Lab: MELD Score | 1.34 [1.16–1.55] |
Lab: FIB-4 Score | 1.34 [1.17–1.52] |
Demographics: Baseline Year >= 2020 | 0.75 [0.52–1.09] |
